<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542057</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-CO-302</org_study_id>
    <nct_id>NCT04542057</nct_id>
  </id_info>
  <brief_title>A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD</brief_title>
  <official_title>A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if ensifentrine is safe and effective for the&#xD;
      treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline of Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average FEV1 AUC0-4h post-dose at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline of Average FEV1 AUC0-4h post-dose at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 over 4 hours post-dose at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline of Peak FEV1 over 4 hours post-dose at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline as a weekly average of Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) total score at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline of SGRQ total score at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning trough FEV1 at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline of Morning trough FEV1 at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) responders at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>The proportion of St. George's Respiratory Questionnaire (SGRQ) responders at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline of Rescue medication use at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transitional Dyspnea Index (TDI) at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Transitional Dyspnea Index (TDI) at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening trough FEV1 at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline Evening trough FEV1 at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 at Week 6 and Week 24</measure>
    <time_frame>6 or 24 weeks</time_frame>
    <description>Change from baseline Peak FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning trough FEV1 at Week 6 and Week 24</measure>
    <time_frame>6 or 24 weeks</time_frame>
    <description>Change from baseline morning trough FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening trough FEV1 at Week 6 and Week 24</measure>
    <time_frame>6 or 24 weeks</time_frame>
    <description>Change from baseline evening trough FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-4h at Week 6 and Week 24</measure>
    <time_frame>6 or 24 weeks</time_frame>
    <description>Change from baseline FEV1 AUC0-4h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 6 and Week 12</measure>
    <time_frame>6 or 12 weeks</time_frame>
    <description>Change from baseline E-RS Total Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGRQ responder analysis at Week 6 and Week 12</measure>
    <time_frame>6 or 12 weeks</time_frame>
    <description>Change from baseline SGRQ responder analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDI at Week 6 and Week 12</measure>
    <time_frame>6 or 12 weeks</time_frame>
    <description>Change from baseline TDI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) total score at Weeks 6 and 12</measure>
    <time_frame>6 or 12 weeks</time_frame>
    <description>Change from baseline of SGRQ total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use at Weeks 6 and 12</measure>
    <time_frame>6 or 12 weeks</time_frame>
    <description>Change from baseline of Rescue medication use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ensifentrine Nebulized Suspension; 3 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Nebulized BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ensifentrine</intervention_name>
    <description>Dosage Formulation:&#xD;
Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily 24-week study that will enroll 800 patients and be randomized 5:3 to ensifentrine (3 mg): placebo</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage Formulation:&#xD;
Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily 24-week study that will enroll 800 patients and be randomized 5:3 to ensifentrine (3 mg): placebo</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Informed Consent&#xD;
&#xD;
          1. Capable of giving informed consent indicating that they understand the purpose of the&#xD;
             study and study procedures and agree to comply with the requirements and restrictions&#xD;
             listed in the informed consent form (ICF).&#xD;
&#xD;
             Age and Sex&#xD;
&#xD;
          2. Age: Patient must be 40 to 80 years of age inclusive, at the time of Screening.&#xD;
&#xD;
          3. Sex:&#xD;
&#xD;
               -  Males are eligible to participate if they agree to use contraception as described&#xD;
                  in the contraceptive guidance from Screening and throughout the study and for at&#xD;
                  least 30 days after the last dose of blinded study medication.&#xD;
&#xD;
               -  Females are eligible to participate if they are not pregnant, not breastfeeding,&#xD;
                  and at least one of the following conditions apply:&#xD;
&#xD;
                    1. Not a woman of childbearing potential (WOCBP). Or&#xD;
&#xD;
                    2. A WOCBP who agrees to follow the contraceptive guidance from Screening and&#xD;
                       throughout the study and for at least 30 days after the last dose of blinded&#xD;
                       study medication.&#xD;
&#xD;
             Smoking History&#xD;
&#xD;
          4. Smoking History: Current or former cigarette smokers with a history of cigarette&#xD;
             smoking ≥10 pack years at Screening (Visit 0) [number of pack years = (number of&#xD;
             cigarettes per day / 20) × number of years smoked (eg, 20 cigarettes per day for 10&#xD;
             years, or 10 cigarettes per day for 20 years)]. Pipe and/or cigar use cannot be used&#xD;
             to calculate pack-year history. Former smokers are defined as those who have stopped&#xD;
             smoking for at least 6 months prior to Visit 0. Smoking cessation programs are&#xD;
             permitted during the study.&#xD;
&#xD;
             COPD Diagnosis, Symptoms, Severity and Maintenance Therapy&#xD;
&#xD;
          5. COPD Diagnosis: Patients with an established clinical history of COPD as defined by&#xD;
             the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines&#xD;
             (Celli BR, 2004) with symptoms compatible with COPD.&#xD;
&#xD;
          6. COPD Symptoms: A score of ≥2 on the Modified Medical Research Council (mMRC) Dyspnea&#xD;
             Scale.&#xD;
&#xD;
          7. COPD Severity:&#xD;
&#xD;
               1. Pre- and Post-albuterol/salbutamol FEV1/FVC ratio of &lt;0.70.&#xD;
&#xD;
               2. Post-albuterol/salbutamol FEV1 ≥30 % and ≤70% of predicted normal calculated&#xD;
                  using the National Health and Nutrition Examination Survey III.&#xD;
&#xD;
          8. Maintenance Therapy: Patients on no maintenance/background therapy or patients on&#xD;
             stable maintenance LAMA or LABA therapy are eligible. Patients taking maintenance LAMA&#xD;
             or LABA therapy must demonstrate stable use of the maintenance LAMA or LABA therapy&#xD;
             for at least 3 months prior to Screening and agree to continue use for the duration of&#xD;
             the study. Background maintenance LAMA or LABA bronchodilator therapy will be capped&#xD;
             at 50% of patients.&#xD;
&#xD;
             Other Requirements for Inclusion&#xD;
&#xD;
          9. Capable of withholding SABAs for 4 hours prior to initiation of any spirometry.&#xD;
             Patients in the maintenance LAMA or LABA therapy stratum must be capable of&#xD;
             withholding Twice-Daily maintenance LAMA or LABA for 24 hours and Once-Daily&#xD;
             maintenance LAMA or LABA for 48 hours prior to initiation of any spirometry.&#xD;
&#xD;
         10. Capable of using the study nebulizer correctly and complying with all study&#xD;
             restrictions and procedures.&#xD;
&#xD;
         11. Ability to perform acceptable spirometry in accordance with ATS/ERS guidelines.&#xD;
&#xD;
        Randomization Criteria Criteria for Inclusion at Randomization&#xD;
&#xD;
          1. Symptoms of COPD: A score of ≥2 on the mMRC Dyspnea Scale.&#xD;
&#xD;
          2. Completion of the e-Diary at least 5 of the last 7 days of the Run-in period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Current Condition or Medical History&#xD;
&#xD;
          1. History of life-threatening COPD including Intensive Care Unit admission and/or&#xD;
             requiring intubation.&#xD;
&#xD;
          2. Hospitalizations for COPD, pneumonia, or Corona Virus Disease 2019 (COVID-19) in the&#xD;
             12 weeks prior to Screening and/or a positive COVID-19 test result indicating an&#xD;
             active infection at Screening. Patients with COVID-19 antibodies from a previous&#xD;
             exposure with no active infection are not excluded.&#xD;
&#xD;
          3. COPD exacerbation requiring oral or parenteral steroids within 3 months of Screening.&#xD;
&#xD;
          4. Previous lung resection or lung reduction surgery within 1-year of Screening.&#xD;
&#xD;
          5. Long term oxygen use defined as oxygen therapy prescribed for greater than 12 hours&#xD;
             per day. As needed oxygen use (≤12 hours per day) is not exclusionary.&#xD;
&#xD;
          6. Pulmonary rehabilitation, unless such treatment has been in a stable maintenance phase&#xD;
             for 4 weeks prior to Visit 1 and remains stable during the study.&#xD;
&#xD;
          7. Lower respiratory tract infection within 6 weeks of Screening.&#xD;
&#xD;
          8. Other respiratory disorders including, but not limited to, a current diagnosis of&#xD;
             asthma, active tuberculosis, lung cancer, sarcoidosis, lung fibrosis, interstitial&#xD;
             lung diseases, unstable sleep apnea, known alpha-1 antitrypsin deficiency, core&#xD;
             pulmonale, clinically significant pulmonary hypertension, clinically significant&#xD;
             bronchiectasis, or other active pulmonary diseases.&#xD;
&#xD;
          9. Major surgery (requiring general anesthesia) in the 6 weeks prior to Screening, lack&#xD;
             of full recovery from surgery at Screening, or planned surgery through the end of the&#xD;
             study.&#xD;
&#xD;
         10. Historical or current evidence of clinically significant cardiovascular disease&#xD;
             defined as any disease that in the opinion of the Investigator would put the safety of&#xD;
             the patient at risk through participation or which could affect the efficacy or safety&#xD;
             analysis if the disease/condition were to exacerbate during the study, including, but&#xD;
             not limited to:&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within 6 months prior to Screening.&#xD;
&#xD;
               -  Unstable or life-threatening cardiac arrhythmia requiring intervention within 3&#xD;
                  months prior to Screening.&#xD;
&#xD;
               -  Diagnosis of New York Heart Association Class III and Class IV heart failure.&#xD;
&#xD;
         11. Chronic uncontrolled disease including, but not limited to, endocrine, active&#xD;
             hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological,&#xD;
             urological, immunological, psychiatric, or ophthalmic diseases that the Investigator&#xD;
             believes are clinically significant.&#xD;
&#xD;
         12. Unstable liver disease defined by the presence of ascites, encephalopathy,&#xD;
             coagulopathy, hypoalbuminemia, esophageal or gastric varices or persistent jaundice,&#xD;
             cirrhosis, known biliary abnormalities (except for Gilbert's syndrome or asymptomatic&#xD;
             gallstones).&#xD;
&#xD;
         13. History of or current malignancy of any organ system, treated or untreated within the&#xD;
             past 5 years, except for localized basal or squamous cell carcinoma of the skin.&#xD;
&#xD;
         14. Findings on physical examination that an investigator considers to be clinically&#xD;
             significant at Screening.&#xD;
&#xD;
             Prior/Concomitant Therapy&#xD;
&#xD;
         15. Use of prohibited medications within the time intervals&#xD;
&#xD;
             History or Suspicion of Drug or Alcohol Abuse&#xD;
&#xD;
         16. Current or history of past drug or alcohol abuse within the past 5 years.&#xD;
&#xD;
             Laboratory and Other Diagnostic Parameters&#xD;
&#xD;
         17. Glomerular Filtration Rate (eGFR) &lt;30 mL/min. The Chronic Kidney Disease Epidemiology&#xD;
             Collaboration Creatinine (2009) calculation will be used.&#xD;
&#xD;
         18. Alanine aminotransferase (ALT) ≥ 2 x upper limit of normal (ULN), alkaline phosphatase&#xD;
             and/or bilirubin &gt; 1.5 x ULN (isolated bilirubin &gt;1.5 x ULN is acceptable if bilirubin&#xD;
             is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
         19. Hepatitis B antibody:&#xD;
&#xD;
               -  Positive findings for both Hepatitis B surface antigen (HBsAg) and Hepatitis B&#xD;
                  core antibody (anti-HBc) are excluded, as this indicates acute or chronic&#xD;
                  infection.&#xD;
&#xD;
               -  Negative findings for HBsAg and Hepatitis B surface antibody (anti-HBs) but&#xD;
                  positive findings for anti-HBc are excluded as this may indicate current or&#xD;
                  resolving infection.&#xD;
&#xD;
               -  Positive findings for anti-HBc and anti-HBs but negative findings for HBsAg are&#xD;
                  not excluded, as this indicates immunity due to natural infection.&#xD;
&#xD;
               -  Positive findings for anti-HBs but negative findings for HBsAg and anti-HBc are&#xD;
                  not excluded, as this indicates immunity due to hepatitis B vaccination.&#xD;
&#xD;
         20. Hepatitis C antibody positive.&#xD;
&#xD;
         21. Any other abnormal hematology, biochemistry, or viral serology deemed by an&#xD;
             investigator to be clinically significantly abnormal. Abnormal chemistry and/or&#xD;
             hematology may be repeated during Screening.&#xD;
&#xD;
         22. Chest X-ray (CXR; posterior-anterior) at Screening, or in the 12 months prior to&#xD;
             Screening with clinically significant abnormalities not attributable to COPD. If a CXR&#xD;
             within the past 12 months is not available but a computerized tomography (CT) scan&#xD;
             within the same time period is available, the CT scan may be reviewed in place of a&#xD;
             CXR. For subjects in Germany, if a CXR or CT scan is not available in the 12 months&#xD;
             prior to Screening, the subject is not eligible for the study.&#xD;
&#xD;
         23. Electrocardiogram (ECG) finding that is significantly abnormal on the 12-lead ECG&#xD;
             obtained at Screening.&#xD;
&#xD;
             Other Exclusions&#xD;
&#xD;
         24. Use of an experimental drug within 30 days or 5 half-lives of Screening, whichever is&#xD;
             longer, and/or participation in a study treatment-free follow-up phase of a clinical&#xD;
             trial within 30 days prior to Screening.&#xD;
&#xD;
         25. Use of an experimental medical device or participation in a follow-up phase of an&#xD;
             experimental medical device clinical trial within 30 days prior to Screening.&#xD;
&#xD;
         26. Intolerance or hypersensitivity to albuterol/salbutamol or ensifentrine (RPL554) or&#xD;
             any of its excipients/components.&#xD;
&#xD;
         27. Prior receipt of blinded study medication in an ensifentrine (RPL554) study.&#xD;
&#xD;
         28. Affiliation with the investigator site, including an Investigator, Sub-Investigator,&#xD;
             study coordinator, study nurse, other employee of participating investigator or study&#xD;
             site or a family member of the aforementioned.&#xD;
&#xD;
         29. Inability to read, understand, and/or complete questionnaires (in the opinion of the&#xD;
             Investigator).&#xD;
&#xD;
         30. A disclosed history or one known to the Investigator of significant non-compliance in&#xD;
             previous investigational studies or with prescribed medications.&#xD;
&#xD;
         31. Any other reason that the Investigator considers makes the patient unsuitable to&#xD;
             participate.&#xD;
&#xD;
        Criteria for Exclusion from Randomization&#xD;
&#xD;
          1. COPD exacerbation or lower respiratory tract infection between Screening and&#xD;
             Randomization (defined as use of any additional treatment other than current treatment&#xD;
             and rescue medication and/or emergency department or hospital visit). Patients with a&#xD;
             severe COPD exacerbation that requires hospitalization may not be rescreened.&#xD;
&#xD;
          2. Positive COVID-19 result at Screening or between Screening and Randomization.&#xD;
&#xD;
          3. Prohibited medication use between Screening Visit 0 and Visit 1.&#xD;
&#xD;
          4. Significantly abnormal ECG finding on the 12-lead ECG obtained at Screening as&#xD;
             assessed by the investigator or site medical doctor/medically qualified person or on&#xD;
             the pre-dose (prior to randomization) ECG obtained at Visit 1. In the event that the&#xD;
             central ECG reviewer discovers a significant ECG abnormality on the Visit 1 ECG, the&#xD;
             patient will be discontinued.&#xD;
&#xD;
          5. Did not meet one or more of the Inclusion Criteria or met one or more of the Exclusion&#xD;
             Criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Margot Macdonald-Berko</last_name>
    <phone>646-413-0307</phone>
    <email>Margot.Macdonald-Berko@veronapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wright Clinical Research, LLC</name>
      <address>
        <city>Alabaster</city>
        <state>Alabama</state>
        <zip>35007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Thomas, MD</last_name>
      <phone>205-419-7738</phone>
      <email>Alanthomas@wrightclinical.com</email>
    </contact>
    <investigator>
      <last_name>Alan Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SEC Clinical Research</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <zip>36420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Garver Jr., MD</last_name>
      <phone>334-504-7014</phone>
      <email>rg@secclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Robert Garver Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jasper Summit Research LLC</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Westerman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jan Westerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates Clinical Trials</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Gotfried, MD</last_name>
      <phone>602-258-4951</phone>
      <phone_ext>Opt7</phone_ext>
      <email>mgotfried@aol.com</email>
    </contact>
    <investigator>
      <last_name>Mark Gotfried, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Arizona, LLC</name>
      <address>
        <city>Sun City West</city>
        <state>Arizona</state>
        <zip>85375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jalal Abbas, MD</last_name>
      <phone>623-223-1580</phone>
      <email>jabbas@criofaz.com</email>
    </contact>
    <investigator>
      <last_name>Jalal Abbas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antelope Valley Clinical Trials</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Tan, MD</last_name>
      <phone>661-266-8944</phone>
      <email>ricardoatan@aol.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Downtown LA Research Center, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salil Nadkarni, MD</last_name>
      <phone>213-261-3680</phone>
      <email>SNadkarni@dtlaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Salil Nadkarni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Medical Research Associates</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Vadgama, MD</last_name>
      <phone>818-349-1979</phone>
      <email>vadgamamd.cmra@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sanjay Vadgama, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials of Sacramento, Inc.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Jordan, MD</last_name>
      <phone>916-525-3377</phone>
      <email>drjordan@cctsac.com</email>
    </contact>
    <investigator>
      <last_name>Rebecca Jordan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasuko Kidokoro, MD</last_name>
      <phone>858-505-0069</phone>
      <email>dr.kidokoro.irc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yasuko Kidokoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of HealthCare Assessment, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Brazinsky, MD</last_name>
      <phone>619-582-5564</phone>
      <email>sbrazinsky@ihcainc.com</email>
    </contact>
    <investigator>
      <last_name>Shari Brazinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alpine Clinical Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Wilcox, DO</last_name>
      <phone>303-443-7229</phone>
      <email>wilcox@alpineresearch.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Wilcox, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Trevino, MD</last_name>
      <phone>727-584-6368</phone>
      <email>miguelt@innovativeresearchfl.com</email>
    </contact>
    <investigator>
      <last_name>Miguel Trevino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Dunn, MD</last_name>
      <phone>727-466-0078</phone>
      <email>ldunn@crwf.com</email>
    </contact>
    <investigator>
      <last_name>Leonard Dunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites - DeLand Clinical Research Unit</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Rankin, DO</last_name>
      <phone>386-785-2400</phone>
      <email>brankin@accelclinical.com</email>
    </contact>
    <investigator>
      <last_name>Bruce Rankin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riverside Clinical Research</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Chang, MD</last_name>
      <phone>386-428-7730</phone>
      <email>mchang@riversideclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Margaret Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Research of Central Florida</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Diaz, MD</last_name>
      <phone>352-435-7240</phone>
      <email>DPI@ClinicalSitePartners.com</email>
    </contact>
    <investigator>
      <last_name>Jose Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Axcess Medical Research</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>13005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Nam, MD</last_name>
      <phone>561-429-8367</phone>
      <email>pnam@axcessmr.com</email>
    </contact>
    <investigator>
      <last_name>Pedro Nam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuren Medical &amp; Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Vaca, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Vaca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Sotolongo, MD</last_name>
      <phone>305-279-3545</phone>
      <email>rsotolongo@miamimedtrials.com</email>
    </contact>
    <investigator>
      <last_name>Roberto Sotolongo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Pelayo, MD</last_name>
      <phone>305-554-6198</phone>
      <email>epelayomd@amriresearch.com</email>
    </contact>
    <investigator>
      <last_name>Enrique Pelayo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Florida. LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Krainson, MD</last_name>
      <phone>305-255-7452</phone>
      <email>JKrainson@Clinicalsitepartners.com</email>
    </contact>
    <investigator>
      <last_name>James Krainson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Medical Research Group, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Lam, MD</last_name>
      <phone>305-969-9707</phone>
      <email>manmiclam@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Institute for Clinical Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Humberto Cruz, DO</last_name>
      <phone>407-658-0966</phone>
      <email>hcruz@ficresearch.com</email>
    </contact>
    <investigator>
      <last_name>Humberto Cruz, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Pulmonary Critical Care</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hudman Hoo, MD</last_name>
      <phone>727-822-6661</phone>
      <email>hhooresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hudman Hoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pasadena Center for Medical Research, LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Ali, MD</last_name>
      <phone>727-347-5242</phone>
      <email>Mohamed.ali@theiaclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Mohamed Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarasota Clinical Research</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugh Windom, MD</last_name>
      <phone>941-927-4888</phone>
      <email>hugh@windomallergy.com</email>
    </contact>
    <investigator>
      <last_name>Hugh Windom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lon Lynn, DO</last_name>
      <phone>813-870-1292</phone>
      <email>llynn@crwf.com</email>
    </contact>
    <investigator>
      <last_name>Lon Lynn, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Trials of Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sady Alpizar, MD</last_name>
      <phone>813-873-8102</phone>
      <email>s.alpizar.md@crtfi.com</email>
    </contact>
    <investigator>
      <last_name>Sady Alpizar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Pulmonary Research Institute, LLC</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faisal A Fakih, MD</last_name>
      <phone>407-740-8078</phone>
      <email>ffakih@fpri.com</email>
    </contact>
    <investigator>
      <last_name>Faisal A Fakih, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Adams, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mark Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMR New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Vargas, MD</last_name>
      <phone>504-821-8158</phone>
      <phone_ext>269</phone_ext>
      <email>Ramon.Vargas@amrllc.com</email>
    </contact>
    <investigator>
      <last_name>Ramon Vargas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesis Clin RES&amp; Consulting</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Sousa, MD</last_name>
      <phone>508-672-5100</phone>
      <email>dfsousa@genesisresearch1.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Sousa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Grullon, MD</last_name>
      <phone>952-852-5279</phone>
      <email>dr.grullon@mnlungresearch.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Grullon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Wright, MD</last_name>
      <phone>952-852-5258</phone>
      <email>dr.wright@mnlungresearch.com</email>
    </contact>
    <investigator>
      <last_name>Patrick Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Chest Consultants</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Siler, MD</last_name>
      <phone>636-946-1650</phone>
      <email>Thomas.siler.md@midwestchest.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Siler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montana Medical Research Inc.</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Sellman, MD</last_name>
      <phone>406-543-0550</phone>
      <email>rsellman@montanamedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Richard Sellman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHEAR Center LLC</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bernard, MD</last_name>
      <phone>347-270-1111</phone>
      <email>david@chearcenter.com</email>
    </contact>
    <investigator>
      <last_name>David Bernard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Health Physicians, P.C.</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherif El Bayadi, MD</last_name>
      <phone>315-475-8402</phone>
      <email>sgelbayadi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Sherif El Bayadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Hudson Medical Research</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sashi Makam, MD</last_name>
      <phone>844-337-8839</phone>
      <email>smakam@mhmresearch.com</email>
    </contact>
    <investigator>
      <last_name>Sashi Makam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28273</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emeka Eziri, MD</last_name>
      <phone>704-290-4587</phone>
      <email>Eeziri@carolinaclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Emeka Eziri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Health Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selwyn Spangenthal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Selwyn Spangenthal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Gastonia</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anup Banerjee, MD</last_name>
      <phone>704-675-7144</phone>
      <email>Abanerjee@crgastonia.com</email>
    </contact>
    <investigator>
      <last_name>Anup Banerjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PharmQuest LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Murray, MD</last_name>
      <phone>336-574-8020</phone>
      <email>amurray@pharmquest.biz</email>
    </contact>
    <investigator>
      <last_name>Alexander Murray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monroe Biomedical Research</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Awawu Igbinadolor, MD</last_name>
      <phone>704-283-7359</phone>
      <email>awawu.igbinadolor@monroeresearch.com</email>
    </contact>
    <investigator>
      <last_name>Awawu Igbinadolor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Lake Norman</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sever Surdulescu, MD</last_name>
      <phone>704-659-3060</phone>
      <email>drsurdulescu@crlkn.com</email>
    </contact>
    <investigator>
      <last_name>Sever Surdulescu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Research Center, Inc.</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Jones, MD</last_name>
      <phone>704-487-5228</phone>
      <email>drjonespi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sridhar Guduri, MD</last_name>
      <phone>614-501-6164</phone>
      <email>SGuduri@aventivresearch.com</email>
    </contact>
    <investigator>
      <last_name>Sridhar Guduri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Remington Davis Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Cordasco, DO</last_name>
      <phone>614-487-2560</phone>
      <email>ecordasco@remdavis.com</email>
    </contact>
    <investigator>
      <last_name>Edward Cordasco, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aventiv Research</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy St. John, MD</last_name>
      <phone>614-336-7880</phone>
      <email>rstjohn@aventivresearch.com</email>
    </contact>
    <investigator>
      <last_name>Roy St. John, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OK Clinical Research, LLC</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Hull, DO</last_name>
      <phone>405-285-6811</phone>
      <email>shull@okclinicalresearch.org</email>
    </contact>
    <investigator>
      <last_name>Michael Hull, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Medford (Crisor, LLC)</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregg Lucksinger, MD</last_name>
      <phone>541-858-1018</phone>
      <phone_ext>0</phone_ext>
      <email>medfordregulatory@velocityclinical.com</email>
    </contact>
    <investigator>
      <last_name>Gregg Lucksinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Safe Harbor Clinical Research</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herman Ayvazyan, MD</last_name>
      <phone>401-431-6611</phone>
      <email>hasafeharbor@aol.com</email>
    </contact>
    <investigator>
      <last_name>Herman Ayvazyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VitaLink Research Anderson</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gowdhami Mohan, MD</last_name>
      <phone>864-965-0190</phone>
      <email>Gmohan.md@vitalinkresearch.com</email>
    </contact>
    <investigator>
      <last_name>Gowdhami Mohan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lowcountry Lung and Critical Care, P.A.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kaelin, DO</last_name>
      <phone>843-572-1255</phone>
      <email>tkaelin@lowcountrylung.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Kaelin, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VitaLink Research Columbia</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles A Thompson, MD</last_name>
      <phone>803-766-2680</phone>
      <email>cthompson.md@vitalinkresearch.com</email>
    </contact>
    <investigator>
      <last_name>Charles A Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Research Partners</name>
      <address>
        <city>Fort Mill</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Shah, MD</last_name>
      <phone>803-802-4561</phone>
      <email>pi@prpstudy.com</email>
    </contact>
    <investigator>
      <last_name>Amit Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VitaLink Research Gaffney</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Erb, MD</last_name>
      <phone>864-488-1283</phone>
      <email>derb.md@vitalinkresearch.com</email>
    </contact>
    <investigator>
      <last_name>David Erb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VitaLink Research - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis De la Cruz, MD</last_name>
      <phone>864-770-0890</phone>
      <email>Ldelacruz.md@vitalinkresearch.com</email>
    </contact>
    <investigator>
      <last_name>Luis De la Cruz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Lancaster</name>
      <address>
        <city>Lancaster</city>
        <state>South Carolina</state>
        <zip>29720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Shealy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Keith Shealy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Rock Hill</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Denenberg, MD</last_name>
      <phone>803-251-9502</phone>
      <email>mdenenberg@cresrh.com</email>
    </contact>
    <investigator>
      <last_name>Michael Denenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Fogarty, MD</last_name>
      <phone>864-583-1556</phone>
      <email>cfogarty@medresearch.com</email>
    </contact>
    <investigator>
      <last_name>Charles Fogarty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VitaLink Research Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Feldman, MD</last_name>
      <phone>864-515-0092</phone>
      <email>Gfeldman.md@vitalinkresearch.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CU Pharmaceutical Research</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Boscia, MD</last_name>
      <phone>864-427-1172</phone>
      <phone_ext>5501</phone_ext>
      <email>jboscia.md@vitalinkresearch.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Boscia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MultiSpecialty Clinical Research, Inc.</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Johnson, MD</last_name>
      <phone>423-794-5520</phone>
      <email>fpjmd@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Frank Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Phase Research Development</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyne Davidson, MD</last_name>
      <phone>865-200-8364</phone>
      <email>emdavidson@newphaseonline.com</email>
    </contact>
    <investigator>
      <last_name>Evelyne Davidson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PnP Research</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Mooring, MD</last_name>
      <phone>806-683-8940</phone>
      <email>Tmooringadc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Mooring, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TTS Research</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Fuentes, MD</last_name>
      <phone>830-249-3602</phone>
      <email>Dfuentes@ttsresearch.com</email>
    </contact>
    <investigator>
      <last_name>David Fuentes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Corsicana Medical Research, PLLC</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Updegrove, MD</last_name>
      <phone>903-872-3005</phone>
      <phone_ext>0352</phone_ext>
      <email>jupdegrove@msacorsicana.com</email>
    </contact>
    <investigator>
      <last_name>John Updegrove, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Pulmonary and Sleep Allergy and Asthma Associates</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dileep Puppala, MD</last_name>
      <phone>949-491-0710</phone>
      <email>Dpuppala@horizoncrg.com</email>
    </contact>
    <investigator>
      <last_name>Dileep Puppala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metroplex Pulmonary and Sleep Center</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahrukh Kureishy, MD</last_name>
      <phone>972-838-1892</phone>
      <email>Shahrukh_kureishy@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Shahrukh Kureishy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Andrews, MD</last_name>
      <phone>210-692-7157</phone>
      <email>dr.andrews@dxrg.com</email>
    </contact>
    <investigator>
      <last_name>Charles Andrews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Element Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Marks, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Marks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sherman Clinical Research</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muqdad Zuriqat, MD</last_name>
      <phone>903-771-4093</phone>
      <email>zuriqat@auroraclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Muqdad Zuriqat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustafa Naeem, MD</last_name>
      <phone>281-517-0550</phone>
      <email>drnaeem@dmclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Mustafa Naeem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nabil Andrawis, MD</last_name>
      <phone>703-330-1112</phone>
      <email>nabil@andrawis.com</email>
    </contact>
    <investigator>
      <last_name>Nabil Andrawis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Principle Research Solutions</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Gower, MD</last_name>
      <phone>509-474-1107</phone>
      <email>Rgower@marycliffallergy.com</email>
    </contact>
    <investigator>
      <last_name>Richard Gower, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Raskin, MD</last_name>
      <phone>+3238213107</phone>
      <email>jo.raskin@uza.be</email>
    </contact>
    <investigator>
      <last_name>Jo Raskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.H.R. de la Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffroy De Fooz, MD</last_name>
      <phone>+3243217047</phone>
      <email>geoffroy.defooz@chrcitadelle.be</email>
    </contact>
    <investigator>
      <last_name>Geoffroy De Frooz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Maarten</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel Lins, MD</last_name>
      <phone>+3215892040</phone>
      <email>muriel.lins@emmaus.be</email>
    </contact>
    <investigator>
      <last_name>Muriel Lins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice RESPISOM Namur</name>
      <address>
        <city>Namur</city>
        <zip>5101</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Benoît Martinot, MD</last_name>
      <phone>+32495502608</phone>
      <email>martinot.j@scarlet.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Benoît Martinot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Himpe, MD</last_name>
      <phone>+3251237119</phone>
      <email>ulrike.himpe@azdelta.be</email>
    </contact>
    <investigator>
      <last_name>Ulrike Himpe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHAT 'Puls' AD</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellina Smilkova, MD</last_name>
      <phone>+359888690478</phone>
      <email>dr.smilkova@mbalpuls.bg</email>
    </contact>
    <investigator>
      <last_name>Ellina Smilkova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Centre &quot;Asklepii&quot;, OOD</name>
      <address>
        <city>Dupnitsa</city>
        <zip>2600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Gyuzeleva, MD</last_name>
      <phone>+359898523224</phone>
      <email>dr.gyuzeleva@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elena Gyuzeleva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University First MHAT-Sofia, &quot;St. Joan Krastitel&quot; EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1142</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginka Kirkova, MD</last_name>
      <phone>+35924034546</phone>
      <email>kirkovaginka@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Ginka Kirkova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NMTH &quot;Tsar Boris III&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sotir Sotirov, MD</last_name>
      <phone>+359 885572845</phone>
      <email>s_sotirov14@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Sotir Sotirov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Lyulin&quot;, EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1336</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Borislav Lund, MD</last_name>
      <phone>+35924034546</phone>
      <email>dr_lund@mail.bg</email>
    </contact>
    <investigator>
      <last_name>Borislav Lund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Nov Rehabilitatsionen Tsentar&quot;, EOOD</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimo Dimov, AProf</last_name>
      <phone>+359888750289</phone>
      <email>dmdimov65@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dimo Dimov, AProf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SHATPPD &quot;Dr. Treyman&quot; EOOD</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stela Dencheva, MD</last_name>
      <phone>+359889916361</phone>
      <email>stella_dencheva@mail.bg</email>
    </contact>
    <investigator>
      <last_name>Stela Dencheva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SHATPPD - Vratsa, EOOD</name>
      <address>
        <city>Vratsa</city>
        <zip>3000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nezabravka Haitova, MD</last_name>
      <phone>+359898624655</phone>
      <email>nezabravka_haytova@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Nezabravka Haitova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ALTA Clinical Research Inc.</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5A 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allan Kelly, MD</last_name>
    </contact>
    <investigator>
      <last_name>Allan Kelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synergy Respiratory Care</name>
      <address>
        <city>Sherwood Park</city>
        <state>Alberta</state>
        <zip>T8H 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyle Melenka, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lyle Melenka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dynamic Drug Advancement</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>LIS 2J5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Philteos, MD</last_name>
    </contact>
    <investigator>
      <last_name>George Philteos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Respirology and Rheumatology Associates</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 1T3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syed Anees, MD</last_name>
    </contact>
    <investigator>
      <last_name>Syed Anees, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.I.C. Mauricie Inc.</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Francoeur, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Francoeur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Ulrik, MD</last_name>
      <phone>+4538622177</phone>
      <email>csulrik@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Charlotte Ulrik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Titlestad, MD</last_name>
      <phone>+4565412740</phone>
      <email>ingrid.titlestad@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Ingrid Titlestad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital, Roskilde</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Meyer, MD, PhD</last_name>
      <phone>+4523350972</phone>
      <email>cnm@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Christian Meyer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Estonia Medical Centre Foundation</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pille Mukk, MD</last_name>
      <phone>+3726173120</phone>
      <email>pille.mukk@regionalhaigla.ee</email>
    </contact>
    <investigator>
      <last_name>Pille Mukk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital, Lung Clinic</name>
      <address>
        <city>Tartu</city>
        <zip>50411</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rain Jõgi, MD</last_name>
      <phone>+3727318918</phone>
      <email>rain.jogi@kliinikum.ee</email>
    </contact>
    <investigator>
      <last_name>Rain Jõgi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Kenessey Albert Kórház-Rendelőintézet, Pulmonológiai Osztály</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katalin Gömöri, MD</last_name>
      <phone>+36 20 9147600</phone>
      <email>katalin.gomori@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>Katalin Gömöri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Komlói Egészségcentrum, Bányászati Utókezelő és Éjjeli Szanatórium Egészségügyi Központ</name>
      <address>
        <city>Komló</city>
        <zip>7300</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orsolya Lovasz, MD</last_name>
      <phone>+36704503761</phone>
      <email>dr.lovasz.orsolya@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Orsolya Lovasz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Da Vinci Klinika Infer-Med Kft. Tüdőgyógyászat</name>
      <address>
        <city>Pécs</city>
        <zip>7634</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Papp, MD</last_name>
      <phone>+36306983137</phone>
      <email>drpappm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marta Papp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szarvasi Tüdőgyógyász Kft</name>
      <address>
        <city>Szarvas</city>
        <zip>5540</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jedlinszki, MD</last_name>
      <phone>+36309155939</phone>
      <email>maria.jedlinszki@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Jedlinszki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Csanád-Csongrád Megyei Mellkasi Betegségek Szakkórháza, Tüdőgondozó Intézet</name>
      <address>
        <city>Szeged</city>
        <zip>6722</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrix Bálint, MD</last_name>
      <phone>+36 20 314-9748</phone>
      <email>balint@deszkikorhaz.hu</email>
    </contact>
    <investigator>
      <last_name>Beatrix Bálint, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szent Borbála Kórház, Tüdőgyógyászat</name>
      <address>
        <city>Tatabánya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Csaba Böcskei, MD</last_name>
      <phone>+3634515488</phone>
      <email>csbocskei@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Csaba Böcskei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne All-Med</name>
      <address>
        <city>Kraków</city>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grażyna Pulka, MD, PhD</last_name>
      <phone>+48124223271</phone>
      <email>pulkaallmed@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Grażyna Pulka, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Małopolskie Centrum Alergologii</name>
      <address>
        <city>Kraków</city>
        <zip>31-624</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Małgorzata Bederska, MD</last_name>
      <phone>+48600875555</phone>
      <email>malgorzatabederska@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Małgorzata Bederska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-051</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Pawlukiewicz, MD</last_name>
      <phone>+48601322053</phone>
      <email>mpawlu@onet.eu</email>
    </contact>
    <investigator>
      <last_name>Malgorzata Pawlukiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabinet Pulmonologii i Diagnostyki Chorób Alergicznych</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorota Małosek, MD</last_name>
      <phone>+48601954735</phone>
      <email>dmalosek@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Dorota Małosek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Alergo-Med&quot; Specjalistyczna Przychodnia Lekarska Sp. Z O. O.</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadetta Majorek-Olechowska, MD</last_name>
      <phone>+48600024455</phone>
      <email>bernadettaolechowska@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bernadetta Majorek-Olechowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych Piotr Napora Lekarze Spółka Partnerska</name>
      <address>
        <city>Wrocław</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Napora, MD</last_name>
      <phone>+48501518188</phone>
      <email>napora.piotr@cbk.wroc.pl</email>
    </contact>
    <investigator>
      <last_name>Piotr Napora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;ALL-MED&quot; Specjalistyczna Opieka Medyczna, Medyczny Instytut Badawczy</name>
      <address>
        <city>Wrocław</city>
        <zip>53-201</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Jutal, Prof.MD, PhD</last_name>
      <phone>+48713633356</phone>
      <email>Marek.jutel@all-med.wroclaw.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Jutel, Prof.MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ETG Łódź</name>
      <address>
        <city>Łódź</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariola Jędrzejczak, MD</last_name>
      <phone>+48422549624</phone>
      <email>mariola.jedrzejczak@polimedica.pl</email>
    </contact>
    <investigator>
      <last_name>Mariola Jędrzejczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pneumologicko-ftizeologická ambulancia, Pneumomed, s.r.o</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mária Drugdová, MD</last_name>
      <phone>+421 903 588 996</phone>
      <email>drugdova@pac.sk</email>
    </contact>
    <investigator>
      <last_name>Mária Drugdová, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MEDEKA s.r.o.</name>
      <address>
        <city>Košice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Pribulova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Erika Pribulova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ambulancia pneumologie a ftizeologie, ZAPA JJ, s.r.o.</name>
      <address>
        <city>Levice</city>
        <zip>93401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Plutinsky, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jan Plutinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Martin, Klinika pneumologie a ftizeologie</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Kocan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ivan Kocan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PNEUMO-MED s.r.o.</name>
      <address>
        <city>Prievidza</city>
        <zip>97101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarina Vircikova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Katarina Vircikova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vithas Internacional Xanit</name>
      <address>
        <city>Benalmádena</city>
        <state>Málaga</state>
        <zip>29631</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo de Luiz Martinez, MD</last_name>
      <phone>+34687370922</phone>
      <email>gdeluizmartinez@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Gustavo de Luiz Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Quironsalud Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Raño Perez, MD</last_name>
      <phone>+34627959385</phone>
      <email>anarano1970@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Raño Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelio Arnedillo Munoz, MD</last_name>
      <phone>+34956002721</phone>
      <email>arnedillo@comcadiz.es</email>
    </contact>
    <investigator>
      <last_name>Aurelio Arnedillo Munoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala de Serveis Medics</name>
      <address>
        <city>Girona</city>
        <zip>17005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Roldan Sanchez, MD</last_name>
      <phone>+34627942876</phone>
      <email>juan.roldan@giromedinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Juan Roldan Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Velasco Garrido, MD</last_name>
      <phone>+34951032338</phone>
      <email>jlvelascogarrido@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose Luis Velasco Garrido, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>45010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Signes-Costa Minana, MD</last_name>
      <phone>+34965938700</phone>
      <email>jaimesignescosta@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jaime Signes-Costa Minana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

